medigraphic.com
ISSN 0016-3813 (Impreso)

2008, Número 2

<< Anterior Siguiente >>

Gac Med Mex 2008; 144 (2)


Conceptos básicos del 18F-FDG PET/CT. Definición y variantes normales

Roldán-Valadez E, Vega-González I, Valdivieso-Cárdenas G, Rumoroso-García A, Morales-Santillán O, Osorio-Cardiel L

Idioma: Español
Referencias bibliográficas: 51
Paginas: 137-146
Archivo PDF: 190.79 Kb.


RESUMEN

La tomografía por emisión de positrones con tomografía multicorte (PET/CT) constituye uno de los métodos de diagnóstico por imagen más modernos; esta tecnología llegó a nuestro país en los tres últimos años. Aunque los principios físicos del PET datan de hace más de 30 años, la fusión de las imágenes con la tomografía multicorte en el posprocesamiento, ha marcado un hito en la detección de estructuras anatómicas con una captación anormal de radiofármacos que puede estar relacionada con inflamación o neoplasia. Este artículo presenta una revisión breve de los principios básicos de PET/CT, la física de la generación de un radiofármaco, la adquisición de la imagen, y sobre todo, se muestran ejemplos de las “variantes normales” que presentan una captación aumentada de 18F-FDG, y que no están relacionadas a un proceso neoplásico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Khul DE, Edwars RQ. Image separation radioisotope scanning. Radiology 1963;80:653-662.

  2. Ziegler S. Physical principles, dedicated/coincidence-PET. In: Oehr P, Biersack HJ, Coleman RE, eds. PET and PET/CT in Oncology. New York: Springer; 2004:3-7.

  3. Vega-González IF, Graef-Sánchez A, García-Reyna JC, Ornelas-Arrieta M. Nuevas modalidades de imagen: PET/CT. Rev Med Sur 2005;12:11-25.

  4. Townsend DW, Cherry SR. Combining anatomy and function, the path of the true image fusion. Eur Radiol 2001;11:1968-1974.

  5. McCarthy TJ, Schwarz SW, Welch MJ. Nuclear medicine and PET: and overview. J Chem Ed 1994;71:830-836.

  6. Finn RD. The search for consistency in the manufacture of PET radiopharmaceuticals. Ann Nucl Med 1999;132:379-382.

  7. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847-850.

  8. McCarthy TJ, Welch MJ. The state of positron emitting radionuclide production in 1997. Sem Nucl Med 1997;28:235-246.

  9. Gupta N, Bradfield H. Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms. Semin Nucl Med 1996;26:65-73.

  10. Van Kouwen MC, Oyen WJ, Nagengast FM, Jansen JB. FDG-PET scanning in the diagnosis of gastrointestinal cancers. Scand J Gastroenterol Suppl 2004;241:85-92.

  11. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-1379.

  12. Wechalekar K, Sharma B, Cook G. PET/CT in oncology—a major advance. Clin Radiol 2005;60:1143-1155.

  13. Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res 2006;11:58-65.

  14. Yap JT, Carney JP, Hall NC, Townsend DW. Image-guided cancer therapy using PET/CT. Cancer J 2004;10:221-233.

  15. Schelbert HL. Myocardial metabolism. Assesment of blood flow and substrate metabolism in the myocardium of the normal human heart. In: Schwaiger M, editor. Cardiac positron emission tomography: Norwel Kluwer Academic Publishers; 1996. pp. 207-216.

  16. Jabour BA, Choi Y, Hoh CK, Rege SD, Soong JC, Lufkin RB, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-Dglucose and MR imaging correlation. Radiology 1993;186:27-35.

  17. Pappas GP, Olcott EW, Drace JE. Imaging of skeletal muscle function using (18)FDG PET: force production, activation, and metabolism. J Appl Physiol 2001;90:329-337.

  18. Kelley DE, Williams KV, Price JC. Insulin regulation of glucose transport and phosphorylation in skeletal muscle assessed by PET. Am J Physiol 1999;277: E361-E369.

  19. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77; quiz 150-151.

  20. Shreve PD, Huy Bui CD. Normal variants in FDG PET Imaging. In: Wahl RL, Buchanan JW, eds. Principles and Practice of Positron Emission Tomography. Philadelhpia, PA: Lippincott Williams & Wilkins; 2002. pp. 101-136.

  21. Kostakoglu L, Wong JC, Barrington SF, Cronin BF, Dynes AM, Maisey MN. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med. 1996;37:1771-1773.

  22. Yasuda S, Fujii H, Nakahara T, Nishiumi N, Takahashi W, Ide M, et al. 18FFDG PET detection of colonic adenomas. J Nucl Med 2001;42:989-92.

  23. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med 1995;20:434-435.

  24. Stahl A, Weber WA, Avril N, Schwaiger M. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin 2000;39:241-245.

  25. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998;23:3-7.

  26. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics 1998;18:805-23; discussion 823-824.

  27. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR Am J Roentgenol 1997;169:1675-1680.

  28. Kosuda S, Fisher S, Kison PV, Wahl RL, Grossman HB. Uptake of 2-deoxy-2-[18F]fluoro-D-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nucl Med 1997;11:195-199.

  29. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797-804.

  30. Mikosch P, Wurtz FG, Gallowitsch HJ, Kresnik E, Lind P. F-18-FDG-PET in a patient with Hashimoto’s thyroiditis and MALT lymphoma recurrence of the thyroid. Wien Med Wochenschr 2003;153:89-92.

  31. Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto’s thyroiditis. Hum Pathol 1988;19:1315-1326.

  32. Scholefield JH, Quayle AR, Harris SC, Talbot CH. Primary lymphoma of the thyroid, the association with Hashimoto’s thyroiditis. Eur J Surg Oncol 1992;18:89-92.

  33. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluoro deoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173-1780.

  34. Erasmus JJ, Patz EF Jr., McAdams HP, Murray JG, Herndon J, Coleman RE, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 1997;168:1357-1360.

  35. Weisdorf DJ, Craddock PR, Jacob HS. Glycogenolysis versus glucose transport in human granulocytes: differential activation in phagocytosis and chemotaxis. Blood 1982;60:888-893.

  36. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 2001;26:314-319.

  37. Takahashi M, Momose T, Kameyama M, Ohtomo K. Abnormal accumulation of [18F]fluorodeoxyglucose in the aortic wall related to inflammatory changes: three case informs. Ann Nucl Med 2006;20:361-364.

  38. Zalts R, Hamoud S, Bar-Shalom R, Eilam O, Rozin A, Hayek T. Panaortitis: diagnosis via fluorodeoxyglucose positron emission tomography. Am J Med Sci 2005;330:247-249.

  39. Walter MA, Melzer RA, Graf M, Tyndall A, Muller-Brand J, Nitzsche EU. [18F]FDG-PET of giant-cell aortitis. Rheumatology (Oxford) 2005;44:690-691.

  40. Van der Schueren B, Lambert M. Cough as the presenting symptom of large vessel vasculitis. Clin Rheumatol 2005;24:411-414.

  41. Kosters K, Bleeker-Rovers CP, van Crevel R, Oyen WJ, van der Ven AJ. Aortitis diagnosed by F-18-fluorodeoxyglucose positron emission tomography in a patient with syphilis and HIV coinfection. Infection 2005;33:387-389.

  42. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000;27:822-832.

  43. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998;25:259-264.

  44. Meyer M, Gast T, Raja S, Hubner K. Increased F-18 FDG accumulation in an acute fracture. Clin Nucl Med 1994;19:13-14.

  45. Lowe VJ, Hebert ME, Anscher MS, Coleman RE. Serial evaluation of increased chest wall F-18 fluorodeoxyglucose (FDG). Uptake following radiation therapy in patients with bronchogenic carcinoma. Clin positron Imaging 1998;1:185-191.

  46. Frank A, Lefkowitz D, Jaeger S, Gobar L, Sunderland J, Gupta N, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995;32:1495-1512.

  47. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology. 2000;216:117-121.

  48. Yamada Y, Uchida Y, Tatsumi K, Yamaguchi T, Kimura H, Kitahara H, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998;39:1160-1166.

  49. Stuckensen T, Kovacs AF, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000;28:319-324.

  50. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001;120:521-527.

  51. Shreve PD. Adding structure to function. J Nucl Med 2000;41:1380-1382.




2020     |     www.medigraphic.com